Developing a new generation of TYK2 therapeutics

About

Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.

Leadership

Management

World-class scientists and leaders in small molecule drug discovery and development.

Board of Directors

Investors

PIPELINE

Developing a broad pipeline of best-in-class precision TYK2 inhibitors.

development pipeline

development pipeline


Targeting TYK2

Tyrosine kinase 2 (TYK2) is an enzyme that regulates immune and inflammatory signaling pathways by mediating the effects of cytokines such as IL-23, IL-12, and Type 1 interferons (IFNs). These cytokines are central to both innate and adaptive immune systems, including the functioning of Th17 and Th1 cells. Inhibiting TYK2 has been shown to be beneficial in the treatment of psoriasis, psoriatic arthritis, and lupus (SLE). Additional evidence suggests that TYK2 inhibition could provide benefit in an even broader range of autoimmune disorders such as ulcerative colitis, Crohn’s disease, ankylosing spondylitis, multiple sclerosis, and others.

Traditional approaches to inhibiting TYK2 and other Janus Kinase (JAK) family enzymes through binding in the catalytic kinase domain (JH1 domain) result in poorly selective binding and inhibition due to the nearly identical kinase domain structures shared among JAKs. This lack of selectivity in the inhibition of JAKs may result in safety issues that significantly limit the risk-benefit profile and therefore breadth of application for autoimmune disorders.

TYK2 DOMAIN STRUCTURE

Domain Structure of JAK-family Kinases

By allosterically regulating TYK2 kinase function through binding to the TYK2 pseudokinase domain (JH2 domain), significant improvement in selectivity versus other JAKs can be achieved. Increased selectivity provides the advantage of avoiding safety liabilities of agents known to inhibit JAK2 and/or JAK1. Sudo Biosciences is developing multiple highly potent and selective small molecule TYK2 pseudokinase inhibitors designed to provide fit-for-purpose treatments across a broad range of autoimmune disorders.

Careers

At Sudo Biosciences, we are passionate about developing best-in-class treatments to improve the lives of patients with immune-mediated inflammatory diseases.

We have created a collaborative and inclusive environment that thrives on intellectual curiosity and work in a fast-paced environment. We are dedicated to the recruitment, training and career development of each team member at Sudo.

If you would like to be considered for a position at Sudo Biosciences, please submit your resume and cover letter to careers@sudobio.com.

Contact Us

Sudo Biosciences, Inc.
70 Willow Rd.  |  Suite 200  |  Menlo Park, CA 94025

info@sudobio.com